Retour
55
35
38
48
45
Fourchette du Jour
182,39 €
186,22 €
Fourchette 52 Semaines
122,48 €
212,71 €
Volume
1 574 520
Moyenne 50J / 200J
193,92 €
/
169,71 €
Clôture Précédente
184,07 €
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Healthcare (627 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | 14,0 | 0,3 |
| P/B | 3,0 | 2,9 |
| ROE % | 22,9 | 3,7 |
| Net Margin % | 17,5 | 3,8 |
| Rev Growth 5Y % | 11,9 | 10,0 |
| D/E | 0,6 | 0,2 |
Objectif de Cours des Analystes
Hold
105,50 €
-43.2%
Low: 103,00 €
High: 108,00 €
P/E Prévisionnel
17,9
BPA Prévisionnel
10,30 €
Croissance BPA (est.)
+0,0%
CA Est.
63 B
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2030 |
16,10 €
15,11 € – 16,73 €
|
81 B | 5 |
| FY2029 |
14,41 €
13,52 € – 14,97 €
|
76 B | 2 |
| FY2028 |
12,93 €
9,59 € – 14,37 €
|
71 B | 7 |
Points Clés
Revenue grew 11,93% annually over 5 years — strong growth
Earnings grew 45,77% over the past year
ROE of 22,93% indicates high profitability
Net margin of 17,46% shows strong profitability
Generating 11,77B in free cash flow
P/E of 14,04 — trading at a low valuation
Croissance
Revenue Growth (5Y)
11,93%
Revenue (1Y)8,63%
Earnings (1Y)45,77%
FCF Growth (3Y)33,85%
Qualité
Return on Equity
22,93%
ROIC13,15%
Net Margin17,46%
Op. Margin23,40%
Sécurité
Debt / Equity
0,61
Current Ratio0,94
Interest Coverage8,11
Valorisation
P/E Ratio
14,04
P/B Ratio2,96
EV/EBITDA12,22
Dividend Yield0,04%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 8,63% | Revenue Growth (3Y) | 13,23% |
| Earnings Growth (1Y) | 45,77% | Earnings Growth (3Y) | 31,23% |
| Revenue Growth (5Y) | 11,93% | Earnings Growth (5Y) | 209,34% |
| Profitability | |||
| Revenue (TTM) | 58,74B | Net Income (TTM) | 10,26B |
| ROE | 22,93% | ROA | 8,99% |
| Gross Margin | 81,90% | Operating Margin | 23,40% |
| Net Margin | 17,46% | Free Cash Flow (TTM) | 11,77B |
| ROIC | 13,15% | FCF Growth (3Y) | 33,85% |
| Safety | |||
| Debt / Equity | 0,61 | Current Ratio | 0,94 |
| Interest Coverage | 8,11 | Dividend Yield | 0,04% |
| Valuation | |||
| P/E Ratio | 14,04 | P/B Ratio | 2,96 |
| P/S Ratio | 2,45 | PEG Ratio | 0,07 |
| EV/EBITDA | 12,22 | Dividend Yield | 0,04% |
| Market Cap | 144,01B | Enterprise Value | 168,00B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 58,74B | 54,07B | 45,81B | 44,35B | 37,42B |
| Net Income | 10,26B | 7,04B | 5,96B | 3,29B | 112,00M |
| EPS (Diluted) | 13,08 | 4,50 | 7,62 | 4,22 | 0,16 |
| Gross Profit | 48,11B | 43,87B | 37,54B | 31,96B | 24,98B |
| Operating Income | 13,74B | 10,00B | 8,19B | 3,76B | 1,06B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 114,07B | 104,04B | 101,12B | 96,48B | 105,36B |
| Total Liabilities | 65,36B | 63,16B | 61,95B | 59,43B | 66,08B |
| Shareholders' Equity | 48,67B | 40,79B | 39,14B | 37,04B | 39,27B |
| Total Debt | 29,70B | 30,11B | 28,62B | 29,14B | 30,69B |
| Cash & Equivalents | 5,71B | 5,49B | 5,84B | 6,17B | 6,33B |
| Current Assets | 28,72B | 25,83B | 25,05B | 22,59B | 26,24B |
| Current Liabilities | 30,62B | 27,87B | 30,54B | 26,29B | 22,59B |
Scores de Stratégies
This stock passed the criteria for 5 strategies
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#305 of 1052
Custom
Capital Light Compounder
#137 of 218
Growth + Value
Growth at a Reasonable Price (Peter Lynch)
#264 of 332
Custom
Balanced Risk
#60 of 151
Custom
Lower Risk
#71 of 140
Activité Récente
Entré
Cash Flow Compounder
Mar 24, 2026
Entré
Capital Light Compounder
Mar 24, 2026
Entré
Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026
Entré
Balanced Risk
Mar 24, 2026
Entré
Lower Risk
Mar 24, 2026